In the study, which enrolled 887 patients, 73% of patients receiving Lexiva/ritonavir maintained suppression of viral replication after 48 weeks of dosing, compared with 71% of patients receiving Kaletra.
The companies said that results will be submitted to the FDA and other health regulatory authorities when the final analysis is concluded.
Lexiva/ritonavir was compared to Kaletra in this study due to Kaletra's position as the preferred HIV protease inhibitor in treatment guidelines developed by the US Department of health and human services and the International AIDS society.
Based on these results from this study, researchers have concluded that Lexiva appears to be comparable to Kaletra and has met the primary endpoints of this non-inferiority trial.